Caredx to report first quarter 2023 financial results

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2023 after market close on wednesday, may 10, 2023. company management will host a corresponding conference call beginning at 1:30 p.m. pacific time / 4:30 p.m. eastern time. individuals interested in listening to the conference call may do so by dialing 1-800-732-8470 for domestic callers or 1-212-231-2912 for international callers. please reference conference id: 22026935. to listen to a live webcast, please visit the investor relations section of caredx’s website at: investors.caredxinc.com. about caredx – the transplant company caredx, inc., headquartered in brisbane, california, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. caredx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. for more information, please visit: www.caredx.com.
CDNA Ratings Summary
CDNA Quant Ranking